Loading...

Jack Bui

TitleAssociate Professor In Residence
InstitutionUniversity of California San Diego
DepartmentPathology
Address9500 Gilman Drive #0612
La Jolla CA 92093
Phone858-534-3890
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Bui studies how to initiate innate immune responses to cancer. His basic research lab uses mouse and human model systems to elucidate genes involved in tumor rejection. Dr. Bui also directs Clinical Flow Cytometry, Diagnostic Immunology, and Stem Cell Processing. His clinical interests include bone marrow transplantation, stem cell regeneration, and autoimmune disease.


    Collapse Research 
    Collapse Research Activities and Funding
    Innate anti-tumor immune responses
    NIH/NCI R01CA157885Aug 2, 2011 - May 31, 2016
    Role: Principal Investigator
    The function and regulation of histocompatibility antigen 60 in cancer
    NIH/NCI K08CA128893Aug 1, 2008 - Jul 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Strnadel J, Carromeu C, Bardy C, Navarro M, Platoshyn O, Glud AN, Marsala S, Kafka J, Miyanohara A, Kato T, Tadokoro T, Hefferan MP, Kamizato K, Yoshizumi T, Juhas S, Juhasova J, Ho CS, Kheradmand T, Chen P, Bohaciakova D, Hruska-Plochan M, Todd AJ, Driscoll SP, Glenn TD, Pfaff SL, Klima J, Ciacci J, Curtis E, Gage FH, Bui J, Yamada K, Muotri AR, Marsala M. Survival of syngeneic and allogeneic iPSC-derived neural precursors after spinal grafting in minipigs. Sci Transl Med. 2018 May 09; 10(440). PMID: 29743351.
      View in: PubMed
    2. Klann JE, Kim SH, Remedios KA, He Z, Metz PJ, Lopez J, Tysl T, Olvera JG, Ablack JN, Cantor JM, Boland BS, Yeo G, Zheng Y, Lu LF, Bui J, Ginsberg MH, Petrich BG, Chang JT. Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance. J Immunol. 2018 Apr 27. PMID: 29703862.
      View in: PubMed
    3. Meier A, Gross ETE, Schilling JM, Seelige R, Jung Y, Santosa E, Searles S, Lin T, Tu XM, Patel HH, Bui J. Isoflurane Impacts Murine Melanoma Growth in a Sex-Specific, Immune-Dependent Manner: A Brief Report. Anesth Analg. 2018 Mar 21. PMID: 29570154.
      View in: PubMed
    4. Searles SC, Santosa EK, Bui J. Cell-cell fusion as a mechanism of DNA exchange in cancer. Oncotarget. 2018 Jan 19; 9(5):6156-6173. PMID: 29464062.
      View in: PubMed
    5. Scheuermann RH, Bui J, Wang HY, Qian Y. Automated Analysis of Clinical Flow Cytometry Data: A Chronic Lymphocytic Leukemia Illustration. Clin Lab Med. 2017 Dec; 37(4):931-944. PMID: 29128077.
      View in: PubMed
    6. Gutkind JS, Bui J. The Next Frontier: Head and Neck Cancer Immunoprevention. Cancer Prev Res (Phila). 2017 Dec; 10(12):681-683. PMID: 29138137.
      View in: PubMed
    7. Seelige R, Searles S, Bui J. Innate sensing of cancer's non-immunologic hallmarks. Curr Opin Immunol. 2018 Feb; 50:1-8. PMID: 29032295.
      View in: PubMed
    8. Widjaja CE, Olvera JG, Metz PJ, Phan AT, Savas JN, de Bruin G, Leestemaker Y, Berkers CR, de Jong A, Florea BI, Fisch K, Lopez J, Kim SH, Garcia DA, Searles S, Bui J, Chang AN, Yates JR, Goldrath AW, Overkleeft HS, Ovaa H, Chang JT. Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. J Clin Invest. 2017 Oct 02; 127(10):3609-3623. PMID: 28846070.
      View in: PubMed
    9. Seelige R, Searles S, Bui J. Mechanisms regulating immune surveillance of cellular stress in cancer. Cell Mol Life Sci. 2018 Jan; 75(2):225-240. PMID: 28744671.
      View in: PubMed
    10. Strnadel J, Choi S, Fujimura K, Wang H, Zhang W, Wyse M, Wright T, Gross E, Peinado C, Park HW, Bui J, Kelber J, Bouvet M, Guan KL, Klemke RL. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. Cancer Res. 2017 04 15; 77(8):1997-2007. PMID: 28381547.
      View in: PubMed
    11. Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui J. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant. 2017 Apr; 23(4):625-634. PMID: 28104514.
      View in: PubMed
    12. Gross ET, Han S, Vemu P, Peinado CD, Marsala M, Ellies LG, Bui J. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. Oncoimmunology. 2017; 6(2):e1268310. PMID: 28344881.
      View in: PubMed
    13. Seelige R, Washington A, Bui J. The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance. Cytokine. 2017 03; 91:10-12. PMID: 27940089.
      View in: PubMed
    14. Saddawi-Konefka R, Seelige R, Gross ET, Levy E, Searles SC, Washington A, Santosa EK, Liu B, O'Sullivan TE, Harismendy O, Bui J. Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. Cell Rep. 2016 08 30; 16(9):2348-58. PMID: 27545889; PMCID: PMC5007173.
    15. Doedens AL, Rubinstein MP, Gross ET, Best JA, Craig DH, Baker MK, Cole DJ, Bui J, Goldrath AW. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811. PMID: 27485135.
      View in: PubMed
    16. Banno A, Garcia DA, van Baarsel ED, Metz PJ, Fisch K, Widjaja CE, Kim SH, Lopez J, Chang AN, Geurink PP, Florea BI, Overkleeft HS, Ovaa H, Bui J, Yang J, Chang JT. Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition. Oncotarget. 2016 Apr 19; 7(16):21527-41. PMID: 26930717; PMCID: PMC5008303.
    17. Bloy N, Sauvat A, Chaba K, Buqué A, Humeau J, Bravo-San Pedro JM, Bui J, Kepp O, Kroemer G, Senovilla L. Morphometric analysis of immunoselection against hyperploid cancer cells. Oncotarget. 2015 Dec 01; 6(38):41204-15. PMID: 26517677; PMCID: PMC4747400.
    18. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui J, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. PMID: 25667416; PMCID: PMC4355235.
    19. Edwards BA, Harris TL, Floersh H, Lukens JR, Zaki MH, Vogel P, Kanneganti TD, Bui J, McGargill MA. Drak2 is not required for tumor surveillance and suppression. Int Immunol. 2015 Mar; 27(3):161-6. PMID: 25568303; PMCID: PMC4817074.
    20. Saddawi-Konefka R, O'Sullivan T, Gross ET, Washington A, Bui J. Tumor-expressed IL-17D recruits NK cells to reject tumors. Oncoimmunology. 2014 Dec; 3(12):e954853. PMID: 25964859.
      View in: PubMed
    21. Hu J, Jo M, Eastman BM, Gilder AS, Bui J, Gonias SL. uPAR induces expression of transforming growth factor ß and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages. Am J Pathol. 2014 Dec; 184(12):3384-93. PMID: 25310970; PMCID: PMC4258500.
    22. Läubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui J, Varki A. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014 Sep 30; 111(39):14211-6. PMID: 25225409; PMCID: PMC4191788.
    23. Pearce OM, Läubli H, Bui J, Varki A. Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Oncoimmunology. 2014; 3:e29312. PMID: 25083340.
      View in: PubMed
    24. O'Sullivan T, Saddawi-Konefka R, Gross E, Tran M, Mayfield SP, Ikeda H, Bui J. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep. 2014 May 22; 7(4):989-98. PMID: 24794441; PMCID: PMC4084720.
    25. Dolezalova D, Hruska-Plochan M, Bjarkam CR, Sørensen JC, Cunningham M, Weingarten D, Ciacci JD, Juhas S, Juhasova J, Motlik J, Hefferan MP, Hazel T, Johe K, Carromeu C, Muotri A, Bui J, Strnadel J, Marsala M. Pig models of neurodegenerative disorders: Utilization in cell replacement-based preclinical safety and efficacy studies. J Comp Neurol. 2014 Aug 15; 522(12):2784-801. PMID: 24610493.
      View in: PubMed
    26. Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui J, Varki A. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5998-6003. PMID: 24711415; PMCID: PMC4000847.
    27. Gross E, Sunwoo JB, Bui J. Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J. 2013 Nov-Dec; 19(6):483-9. PMID: 24270347.
      View in: PubMed
    28. Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HE, Bui J, Sunwoo JB. Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2013 Jul 23; 110(30):12391-6. PMID: 23836658; PMCID: PMC3725066.
    29. Tran M, Henry RE, Siefker D, Van C, Newkirk G, Kim J, Bui J, Mayfield SP. Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners. Biotechnol Bioeng. 2013 Nov; 110(11):2826-35. PMID: 23719862.
      View in: PubMed
    30. Sevc J, Goldberg D, van Gorp S, Leerink M, Juhas S, Juhasova J, Marsala S, Hruska-Plochan M, Hefferan MP, Motlik J, Rypacek F, Machova L, Kakinohana O, Santucci C, Johe K, Lukacova N, Yamada K, Bui J, Marsala M. Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: effect on spinally grafted human neural precursor survival. Exp Neurol. 2013 Oct; 248:85-99. PMID: 23748136.
      View in: PubMed
    31. Peinado C, Kang X, Hardamon C, Arora S, Mah S, Zhang H, Ngolab J, Bui J. The nuclear factor-?B pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-?B inhibitors in cancer therapy. Immunology. 2013 Jun; 139(2):265-74. PMID: 23350962; PMCID: PMC3647192.
    32. Tran M, Van C, Barrera DJ, Pettersson PL, Peinado CD, Bui J, Mayfield SP. Production of unique immunotoxin cancer therapeutics in algal chloroplasts. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):E15-22. PMID: 23236148; PMCID: PMC3538218.
    33. O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui J. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012 Sep 24; 209(10):1869-82. PMID: 22927549; PMCID: PMC3457735.
    34. Cheney EE, Wise EL, Bui J, Schreiber RD, Carayannopoulos LN, Spitzer D, Zafirova B, Polic B, Shaw AS, Markiewicz MA. A dual function of NKG2D ligands in NK-cell activation. Eur J Immunol. 2012 Sep; 42(9):2452-8. PMID: 22740149; PMCID: PMC3641666.
    35. Kreisel D, Gelman AE, Higashikubo R, Lin X, Vikis HG, White JM, Toth KA, Deshpande C, Carreno BM, You M, Taffner SM, Yokoyama WM, Bui J, Schreiber RD, Krupnick AS. Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res. 2012 Sep 01; 72(17):4311-7. PMID: 22751136; PMCID: PMC3432713.
    36. Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, Verhagen A, Reid C, Lari M, Rizzi E, Balsamo C, Corti G, De Bellis G, Longo L. Specific inactivation of two immunomodulatory SIGLEC genes during human evolution. Proc Natl Acad Sci U S A. 2012 Jun 19; 109(25):9935-40. PMID: 22665810.
      View in: PubMed
    37. Allen CT, Judd NP, Bui J, Uppaluri R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope. 2012 Jan; 122(1):144-57. PMID: 22183634.
      View in: PubMed
    38. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Dunn GP, Bui J, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 Jan 01; 72(1):365-74. PMID: 22086849; PMCID: PMC3286642.
    39. O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui J. Cancer immunoediting of the NK group 2D ligand H60a. J Immunol. 2011 Oct 01; 187(7):3538-45. PMID: 21876033; PMCID: PMC3178735.
    40. Quinn KH, Lacoursiere DY, Cui L, Bui J, Parast MM. The unique pathophysiology of early-onset severe preeclampsia: role of decidual T regulatory cells. J Reprod Immunol. 2011 Sep; 91(1-2):76-82. PMID: 21782252.
      View in: PubMed
    41. Wang X, Chow R, Deng L, Anderson D, Weidner N, Godwin AK, Bewtra C, Zlotnik A, Bui J, Varki A, Varki N. Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology. Glycobiology. 2011 Aug; 21(8):1038-48. PMID: 21467073; PMCID: PMC3130538.
    42. Yadav D, Ngolab J, Dang N, Bui J. Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology. 2011 Jun; 133(2):197-205. PMID: 21438873; PMCID: PMC3088982.
    43. Zhang H, Hardamon C, Sagoe B, Ngolab J, Bui J. Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Mol Immunol. 2011 Jan; 48(4):539-45. PMID: 21093919; PMCID: PMC3030190.
    44. Büchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, Bui J, Gallo RL. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol. 2010 Jan 01; 184(1):369-78. PMID: 19949065; PMCID: PMC2908520.
    45. Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui J. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol. 2009 Jan 01; 182(1):39-43. PMID: 19109132; PMCID: PMC2714222.
    46. Uppaluri R, Sheehan KC, Wang L, Bui J, Brotman JJ, Lu B, Gerard C, Hancock WW, Schreiber RD. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 2008 Jul 15; 86(1):137-47. PMID: 18622291; PMCID: PMC3140461.
    47. Bui J, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007 Apr; 19(2):203-8. PMID: 17292599.
      View in: PubMed
    48. Bui J, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006 Jul 15; 66(14):7301-9. PMID: 16849580.
      View in: PubMed
    49. Bui J, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol. 2006 Jan 15; 176(2):905-13. PMID: 16393975.
      View in: PubMed
    50. McGargill MA, Sharp LL, Bui J, Hedrick SM, Calbo S. Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling. J Immunol. 2005 Jul 15; 175(2):656-64. PMID: 16002660.
      View in: PubMed
    51. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui J, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005 Jul; 6(7):722-9. PMID: 15951814.
      View in: PubMed
    52. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Interferon-gamma and cancer immunoediting. Immunol Res. 2005; 32(1-3):231-45. PMID: 16106075.
      View in: PubMed
    53. Bui J, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002 Oct; 124(4):852-4. PMID: 12324751.
      View in: PubMed